Xeomin
Clinical safety rating: caution
Comprehensive clinical and safety monograph for Xeomin (Xeomin).
IncobotulinumtoxinA inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a presynaptic protein, thereby blocking neurotransmission and causing muscle paralysis.
| Metabolism | Presumed to undergo proteolytic degradation via general protein catabolism; no specific metabolic pathways or enzymes identified. |
| Excretion | Renal (minimal, intact toxin degraded); biliary/fecal (primary, via hepatic metabolism and biliary excretion of inactive fragments). |
| Half-life | Terminal elimination half-life: approximately 10 days (range 6–16 days) for the neurotoxin complex in serum; clinical duration of effect is longer due to prolonged intraneuronal activity. |
| Protein binding | Approximately 85–95% bound to serum proteins, primarily albumin and alpha-2-macroglobulin. |
| Volume of Distribution | Approximately 0.5–1.0 L/kg, indicating distribution primarily into extracellular fluid and muscle tissue. |
| Bioavailability | Intramuscular: 100% (direct injection into muscle); oral: negligible (not clinically used); intravenous: not applicable. |
| Onset of Action | Intramuscular: 1–3 days (initial effect), maximal effect at 2–4 weeks. |
| Duration of Action | Intramuscular: 3–6 months, depending on dose, muscle mass, and individual response; repeated injections may lead to shorter duration due to antibody formation. |
| Molecular Weight | 150 |
Injected intramuscularly; for cervical dystonia: 120-240 Units divided among affected muscles every 12-16 weeks; for blepharospasm: 15-35 Units per eye every 12-16 weeks; for glabellar lines: 20 Units divided into 5 injection sites every 3-4 months.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for any degree of hepatic impairment. |
| Pediatric use | Safety and efficacy not established in patients <18 years; no approved pediatric dosing. |
| Geriatric use | No specific dose adjustment recommended, but consider increased sensitivity and comorbidities; use lowest effective dose and monitor for adverse effects. |
| 1st trimester | Avoid use; risk of fetal harm based on animal studies and limited human data. |
| 2nd trimester | Avoid use; potential for adverse effects on fetal development. |
| 3rd trimester | Avoid use during labor or delivery due to potential interference with uterine contractions. |
Clinical note
Comprehensive clinical and safety monograph for Xeomin (Xeomin).
| Placental transfer | Crosses placenta in animal studies; likely in humans due to molecular size. |
| Breastfeeding | Excretion into human milk unknown; risk of infant botulism. Weigh risk vs benefit; consider temporary cessation. |
| Lactation Rating |
■ FDA Black Box Warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT - The effects of botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism. These symptoms have been reported hours to weeks after injection, and in some cases have been life-threatening. Risk is greatest in children treated for spasticity, but symptoms also occurred in adults. Seek medical attention immediately if swallowing or breathing difficulties occur.
| Serious Effects |
Hypersensitivity to botulinum toxin type A or any excipientInfection at injection siteChronic myasthenia gravisLambert-Eaton syndromeMotor neuron disease
| Precautions | Distant spread of toxin effect (black box warning), Dysphagia and breathing difficulties, Pre-existing neuromuscular disorders may exacerbate weakness, Risk of aspiration in patients with pre-existing swallowing disorders, Injection site reactions, Antibody formation with repeated use, Use with caution in patients with compromised respiratory status, Concomitant use with aminoglycosides or other agents interfering with neuromuscular transmission may potentiate effects |
| Food/Dietary |
Loading safety data…
| L4 (possibly hazardous) |
| Teratogenic Risk | Insufficient human data; animal studies not indicative of increased fetal risk at doses up to 4 U/kg. Given high molecular weight (>150 kDa), systemic absorption is negligible, minimizing fetal exposure. No known teratogenic effects across trimesters. |
| Fetal Monitoring | No specific monitoring required beyond usual obstetric care. Monitor for systemic effects of botulinum toxin (e.g., dysphagia, muscle weakness). |
| Fertility Effects | No human data on fertility. Animal studies showed no adverse effects on male or female fertility at doses up to 4 U/kg. |
| No significant food interactions. No dietary restrictions required. |
| Clinical Pearls | Reconstitute Xeomin only with preservative-free 0.9% Sodium Chloride Injection, USP; use within 4 hours after reconstitution. Antibody formation may occur with repeated use, potentially reducing efficacy; minimum interval between treatments should be at least 12 weeks. Storage before dilution: refrigerate at 2-8°C; after dilution, store at 2-8°C and use within 4 hours. Avoid injection into infected or inflamed areas. Monitor for dysphagia and respiratory difficulty post-injection, especially in patients with neuromuscular disorders. |
| Patient Advice | Notify your doctor immediately if you experience difficulty swallowing, speaking, or breathing, or if you have muscle weakness spreading beyond the injection site. · Avoid rubbing or massaging the treated area for at least 24 hours after injection to prevent spread of the toxin. · Do not receive Xeomin if you have an infection at the planned injection site or are allergic to any ingredient. · Inform your doctor if you are pregnant, breastfeeding, or have any neurological conditions such as amyotrophic lateral sclerosis (ALS) or myasthenia gravis. · Report any intentional muscle weakness, blurred vision, or drooping eyelids to your healthcare provider immediately. · Do not drive or operate heavy machinery until you know how Xeomin affects you, as temporary eye or vision changes may occur. · Keep follow-up appointments to monitor for treatment effects and potential side effects. |